- Radius Health announces the acquisition of the development and commercialization rights for RAD011 from Benuvia Therapeutics.
- The deal economics appear favorable and should add to the top-line growth outlook while also offering diversification benefits.
- Alongside the M&A announcement, the stronger FQ4 ’20 data and fiscal 2021 guide also point toward an accelerated breakeven path.
- With a profitable base business now supplemented by several key catalysts, Radius is a compelling story to own in fiscal 2021.
For further details see:
Radius Health: Latest Pipeline Addition Is A Step In The Right Direction